XML 75 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segments (Tables)
12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Information by Reportable Segment
Information by reportable segment was as follows:
 
PGEN Therapeutics
 
ActoBio
 
MBP Titan
 
Trans Ova
 
All Other
 
Total
Goodwill
 
 
 
 
 
 
 
 
 
 
 
Balances at December 31, 2017
$

 
$

 
$

 
$
46,236

 
$
47,515

 
$
93,751

Reallocations from changes to reporting units
15,232

 
1,788

 

 

 
(17,020
)
 

Foreign currency translation adjustments

 

 

 

 
(124
)
 
(124
)
Balances at December 31, 2018
15,232

 
1,788

 

 
46,236

 
30,371

 
93,627

Reallocations from changes to reporting units

 

 
9,635

 

 
(9,635
)
 

Impairments

 

 

 
(29,642
)
 
(178
)
 
(29,820
)
Foreign currency translation adjustments

 
(53
)
 

 

 

 
(53
)
Balances at December 31, 2019
$
15,232

 
$
1,735

 
$
9,635

 
$
16,594

 
$
20,558

 
$
63,754

 
Year Ended December 31, 2019
 
PGEN Therapeutics
 
ActoBio
 
MBP Titan
 
Trans Ova
 
All Other
 
Total
Revenues from external customers
$
2,227

 
$
(364
)
 
$
3,813

 
$
68,672

 
$
16,227

 
$
90,575

Intersegment revenues
11,341

 
498

 
96

 
1,361

 
1,270

 
14,566

Total segment revenues
$
13,568

 
$
134

 
$
3,909

 
$
70,033

 
$
17,497

 
$
105,141

 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(30,166
)
 
$
(13,662
)
 
$
(36,718
)
 
$
(6,337
)
 
$
(5,952
)
 
$
(92,835
)
 
Year Ended December 31, 2018
 
PGEN Therapeutics
 
ActoBio
 
MBP Titan
 
Trans Ova
 
All Other
 
Total
Revenues from external customers
$
29,021

 
$
6,684

 
$
9,927

 
$
75,178

 
$
30,213

 
$
151,023

Intersegment revenues
617

 
840

 
9

 
558

 
255

 
2,279

Total segment revenues
$
29,638

 
$
7,524

 
$
9,936

 
$
75,736

 
$
30,468

 
$
153,302

 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(32,841
)
 
$
(12,797
)
 
$
(29,403
)
 
$
(5,730
)
 
$
(10,708
)
 
$
(91,479
)
 
Year Ended December 31, 2017
 
PGEN Therapeutics
 
ActoBio
 
MBP Titan
 
Trans Ova
 
All Other
 
Total
Revenues from external customers
$
53,184

 
$
12,929

 
$
14,336

 
$
79,783

 
$
59,174

 
$
219,406

Intersegment revenues

 
1,183

 

 
243

 
630

 
2,056

Total segment revenues
$
53,184

 
$
14,112

 
$
14,336

 
$
80,026

 
$
59,804

 
$
221,462

 
 
 
 
 
 
 
 
 
 
 
 
Segment Adjusted EBITDA
$
(5,655
)
 
$
(2,656
)
 
$
(32,251
)
 
$
1,020

 
$
(1,102
)
 
$
(40,644
)

Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The table below reconciles total segment revenues from reportable segments to total consolidated revenues:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Total segment revenues from reportable segments
$
87,644

 
$
122,834

 
$
161,658

Other revenues, including from other operating segments
18,602

 
30,914

 
59,861

Elimination of intersegment revenues
(15,524
)
 
(2,570
)
 
(2,056
)
Total consolidated revenues
$
90,722

 
$
151,178

 
$
219,463

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Segment Adjusted EBITDA for reportable segments
$
(86,883
)
 
$
(80,771
)
 
$
(39,542
)
All Other Segment Adjusted EBITDA
(5,952
)
 
(10,708
)
 
(1,102
)
Remove cash paid for capital expenditures and investments in affiliates
15,339

 
19,906

 
31,701

Add recognition of previously deferred revenue associated with upfront and milestone payments
17,843

 
39,446

 
68,539

Other expenses:
 
 
 
 
 
Interest expense
(17,666
)
 
(8,473
)
 
(584
)
Depreciation and amortization
(19,789
)
 
(24,105
)
 
(21,609
)
Impairment loss
(30,810
)
 

 
(13,823
)
Reacquisition of in-process research and development

 
(236,748
)
 

Stock-based compensation expense
(16,443
)
 
(32,424
)
 
(36,893
)
Equity in net loss of affiliates
(2,416
)
 
(8,986
)
 
(12,436
)
Other
67

 

 

Unallocated corporate costs
(47,577
)
 
(84,536
)
 
(53,197
)
Eliminations
(14,400
)
 
(2,343
)
 
579

Consolidated net loss from continuing operations before income taxes
$
(208,687
)
 
$
(429,742
)
 
$
(78,367
)